💨 Abstract
Israeli bio-pharmaceutical startup, Kadimastem Ltd., and Swiss bio-pharmaceutical company NLS Limited have approved a merger. Kadimastem, founded in 2009, is a clinical-stage cell therapy company focusing on the expansion and differentiation of Human Embryonic Stem Cells (hESCs). NLS, based in Zurich, specializes in therapies for rare and complex central nervous system disorders.
Courtesy: theprint.in
Summarized by Einstein Beta 🤖
Suggested
Jharkhand contributes significantly to country's exchequer, but nothing for it in Budget: Soren
One killed in fire at biscuit factory in MP's Bhind district
Over 25 acres of illegal poppy cultivation destroyed in Manipur's Tengnoupal district
India’s efforts to unlock deep-sea resources gain public attention at ''Fish Fest'', says CMFRI
Chhattisgarh BJP govt 'failed' to meet people's expectations: Cong; ruling party rejects charges
Helpline to assist senior citizens restarted in J-K
Kumbh: After drop in bookings due to stampede, hotels hopeful of uptick post Basant Panchami snan
Quake of magnitude 3.6 hits Bikaner in Rajasthan
KNVB instructors training 35 football coaches in Jammu
Two smugglers nabbed with heroin packet dropped by Pakistani drone in Punjab's Gurdaspur
Powered by MessengerX.io